Incidence of factor VIII inhibitors throughout life in severe hemophilia A in the United Kingdom

158Citations
Citations of this article
85Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

The age-adjusted incidence of new factor VIII inhibitors was analyzed in all United Kingdom patients with severe hemophilia A between 1990 and 2009. Three hundred fifteen new inhibitors were reported to the National Hemophilia Database in 2528 patients with severe hemophilia who were followed up for a median (interquartile range) of 12 (4-19) years. One hundred sixty (51%) of these arose in patients ≥ 5 years of age after a median (interquartile range) of 6 (4-11) years' follow-up. The incidence of new inhibitors was 64.29 per 1000 treatment-years in patients< 5 years of age and 5.31 per 1000 treatment-years at age 10-49 years, rising significantly (P = . 01) to 10.49 per 1000 treatmentyears in patients more than 60 years of age. Factor VIII inhibitors arise in patients with hemophilia A throughout life with a bimodal risk, being greatest in early childhood and in old age. HIV was associated with significantly fewer new inhibitors. The inhibitor incidence rate ratio in HIVseropositive patients was 0.32 times that observed in HIV-seronegative patients (P < . 001). Further study is required to explore the natural history of later-onset factor VIII inhibitors and to investigate other potential risk factors for inhibitor development in previously treated patients. © 2011 by The American Society of Hematology.

Figures

References Powered by Scopus

Treatment-related risk factors of inhibitor development in previously untreated patients with hemophilia A: The CANAL cohort study

446Citations
N/AReaders
Get full text

Mortality rates, life expectancy, and causes of death in people with hemophilia A or B in the United Kingdom who were not infected with HIV

433Citations
N/AReaders
Get full text

Factor VIII inhibitors in mild and moderate-severity haemophilia A

204Citations
N/AReaders
Get full text

Cited by Powered by Scopus

Current Clinical Applications of In Vivo Gene Therapy with AAVs

480Citations
N/AReaders
Get full text

Factor VIII products and inhibitor development in severe hemophilia A

383Citations
N/AReaders
Get full text

F8 gene mutation type and inhibitor development in patients with severe hemophilia A: Systematic review and meta-analysis

299Citations
N/AReaders
Get full text

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Cite

CITATION STYLE

APA

Hay, C. R. M., Palmer, B., Chalmers, E., Liesner, R., MacLean, R., Rangarajan, S., … Collins, P. W. (2011). Incidence of factor VIII inhibitors throughout life in severe hemophilia A in the United Kingdom. Blood, 117(23), 6367–6370. https://doi.org/10.1182/blood-2010-09-308668

Readers over time

‘11‘12‘13‘14‘15‘16‘17‘18‘19‘20‘21‘22‘23‘24036912

Readers' Seniority

Tooltip

PhD / Post grad / Masters / Doc 29

50%

Researcher 16

28%

Professor / Associate Prof. 11

19%

Lecturer / Post doc 2

3%

Readers' Discipline

Tooltip

Medicine and Dentistry 38

69%

Agricultural and Biological Sciences 8

15%

Biochemistry, Genetics and Molecular Bi... 5

9%

Pharmacology, Toxicology and Pharmaceut... 4

7%

Article Metrics

Tooltip
Mentions
News Mentions: 1

Save time finding and organizing research with Mendeley

Sign up for free
0